Given thatRIT1-related Noonan syndrome is caused by a gain of function in the RAS/RAF/mitogen-activated protein kinase signaling pathway, the mitogen-activated protein kinase inhibitor might be more effective than the mTOR inhibitor in such patients.6, 7. Here, MTOR is linked to Noonan syndrome.